Ryan & Maniskas, LLP Announces Investigation of Chemed Corp.
WAYNE, Pa., May 13, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/che) announces that it is investigating potential claims against Chemed Corporation ("Chemed" or the "Company") (NYSE: CHE) concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by the Company, regarding Chemed's business, operations and prospects were false and misleading.
On May 2, 2013, the U.S. Department of Justice (the "DOJ") sued Chemed and certain affiliates alleging that the Company systematically defrauded Medicare. According to the DOJ, the Company aggressively marketed intensive nursing care to patients who did not need it, and then improperly billed Medicare, sometimes for patients who never even received the care. The Company allegedly submitted fraudulent records and statements in support of these and other Medicare claims.
On this news, Chemed shares fell nearly 20%.
For more information regarding this, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at email@example.com or visit: www.rmclasslaw.com/cases/che. For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.
SOURCE Ryan & Maniskas, LLP
More by this Source
Ryan & Maniskas, LLP Announces Investigation of Target Corp.
Mar 07, 2014, 19:00 ET
Ryan & Maniskas, LLP Announces Investigation of Safeway Inc.
Mar 07, 2014, 10:49 ET
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against LifeLock, Inc.
Mar 05, 2014, 18:15 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.